

Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)

Technology appraisal guidance

Published: 23 July 2025

www.nice.org.uk/guidance/ta1082

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of letermovir for preventing cytomegalovirus infection after a kidney transplant in adults. This is because Merck Sharp & Dohme has confirmed that it does not intend to make an evidence submission for the appraisal. The company considers that there is unlikely to be enough cost-effectiveness evidence to support a decision.

Information

If NHS organisations wish to consider letermovir for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7123-7